Sponsored Content
Biotechnology Industry
Novartis Opens Second Biotech Facility in Austria
The pharmaceutical company Novartis has commissioned its second state-of-the-art cell culture facility for the production of monoclonal antibodies in Kundl (Kufstein district). The opening of the facility, which has been invested in with a total of €500 million, along with its sister facility in Schaftenau (Kufstein district), which opened in June 2024, is seen as a strong signal for the Austrian life sciences sector. With this expansion, Novartis is creating around 100 new jobs in Kundl and strengthening its global production capacity.
October 21, 2025
Tyrolean Biotech Company Cyprumed Closes 493 Million Dollar Deal with American MSD
The Innsbruck-based biotechnology company Cyprumed GmbH is making international headlines with a multi-million dollar license deal: Together with the U.S. pharmaceutical group MSD (Merck & Co., Inc.), the company has signed an agreement worth up to 493 million US dollars. The aim is to develop innovative tablet formulations for peptide drugs - a potential game changer in modern drug therapies.
April 15, 2025
Valneva Completes EUR 45 Million Capital Increase
The listed biotechnology company Valneva SE announces the completion of its capital increase with shareholders preferential subscription rights launched on January 12th, 2015. Valneva estimates net proceeds of EUR 42 millions from 18.2 million offered new shares. The new ordinary shares will be traded on Euronext and on the Prime Market segment of the Vienna Stock Exchange. The financing will mainly be used for the acquisition of Crucell Sweden AB and all assets, licenses and privileges related to Dukoral.
February 4, 2015
Fast News Search
